Verona Pharma
VRNA
VRNA was delisted on the 6th of October, 2025.
40 hedge funds and large institutions have $122M invested in Verona Pharma in 2022 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 8 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
13% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 8
3% more funds holding
Funds holding: 39 → 40 (+1)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0.28% less ownership
Funds ownership: 7.55% → 7.27% (-0.28%)
33% less capital invested
Capital invested by funds: $182M → $122M (-$59.7M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$2.14M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$1.28M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$211K |
| 4 |
BFM
Boothbay Fund Management
New York
|
+$164K |
| 5 |
Renaissance Technologies
New York
|
+$121K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GTC
Ghost Tree Capital
New York
|
-$3.74M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.33M |
| 3 |
Citigroup
New York
|
-$1.84M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$1.5M |
| 5 |
PA
Perceptive Advisors
New York
|
-$552K |
VRNA Hedge Fund Activity: Q2 2022 in Review
40 of the 5,932 institutional investors tracked by Wall St. Rank reported a position in Verona Pharma (VRNA) for Q2 2022, worth a combined $122M — down 33% from $182M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new VRNA positions and 8 closed out — a net gain of 1 holder — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Woodline Partners, opening a new position worth an estimated $2.14M. The largest seller was Ghost Tree Capital, exiting entirely with an estimated $3.74M sold.
- 40 institutional investors held Verona Pharma (VRNA) as of Q2 2022, up from 39 in Q1 2022.
- Funds reported $122M of Verona Pharma stock for Q2 2022, down 33% quarter-over-quarter.
- 9 funds opened new Verona Pharma positions in Q2 2022 and 8 closed out, a net change of +1 holder.
- The largest Verona Pharma buyer in Q2 2022 was Woodline Partners, an estimated $2.14M added.
- The largest Verona Pharma seller in Q2 2022 was Ghost Tree Capital, an estimated $3.74M sold.
Based on aggregated 13F filings for Q2 2022.